

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	NEW 10/556145	
			Filing Date	November 9, 2005	
			First Named Inventor	Richard BÉLIVEAU	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	0480-0165PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/AMG/	AA*	US-6,455,494-B1	09-24-2002	JEFFERIES et al.	
/AMG/	AB*	US-2002/119095-A1	08-29-2002	BROOKS et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
/AMG/	CA	SALA, Roberta et al., European Journal of Cell Biology, vol. 81, no. 11, November 2002, pages 599-607.		
/AMG/	CB	DEMEULE, Michel et al., Blood, vol. 102, no. 5, September 1, 2003, pages 1723-1731.		
/AMG/	CC	ROSE, T.M. et al., Proceedings of the National Academy of Sciences of USA, National Academy of Science. vol. 83, March 1986, pages 1261-1265.		
/AMG/	CD	SCHLINGEMANN, R.O. et al., American Journal of Pathology, vol. 136, no. 6, 1990, pages 1393-1406.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Anne Gussow/	Date Considered	10/05/2007
-----------------------	---------------	--------------------	------------



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/556,145-Conf. #5957		
		Filing Date	August 21, 2006		
		First Named Inventor	Richard BÉLIVEAU		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	1	Attorney Docket Number	0480-0165PUS1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
/AMG/	CA	Alemany et al., 1993, J Cell Sci, 104:1155-1162.		
	CB	Andreasen et al., 1997, Int. J Cancer, 72:1-22.		
	CC	Baker et al., 1992, FEBS Letters, 298(2,3):215-218.		
	CD	Bass et al., 2002, J Biol Chem, 277(49):46845-46848.		
	CE	Brown et al., 1981, Proc Natl Acad Sci USA, 78(1):539-543.		
	CF	Brown et al., 1982, Nature, 296:171-173		
	CG	Bu et al., 1996, J Biol Chem, 271(36):22218-22224		
	CH	Conese et al., 1995, J Cell Biol, 131(6):1609-1622		
	CI	Cubellis et al., 1989, Proc Natl Acad Sci USA, 86:4828-4832		
	CJ	Dano et al., 1985, Adv Cancer Res, 44:139-266		
	CK	Dehouck et al., 1992, J Neurochem, 58 (5):1790-1797		
	CL	Demeule, et al., 2002 J Neurochem 83:924-933		
	CM	Fillebeen et al., 1999 J Biol Chem 274(11):7011-7017		
	CN	Food et al., 1994 J Biol Chem. 269(4):3034-3040		
	CO	Gong et al., 2001 J Biol Chem 276(22):19078-19083		
	CP	Herz et al., 2001J Clin Invest 108(6):779-784		
	CQ	Jefferies et al., 1996 Brain Res 712:122-126		
	CR	Johnsson et al., 1991 Anal Biochem 198:268-277		
	CS	Kennard et al., 1996 Nat Med 2:1230-1235		
	CT	Kozyraki et al., 2001 Proc Natl Acad Sci USA 98(22):12491-12496		
	CU	Li et al., 2002 J Biol Chem 277(44):42366-42371		
	CV	Liu et al., 2002 J. Biol Chem 276(31):28889-28896		
	CW	Min et al., 1996 Cancer Res 56:2428-2433		
	CX	Neels et al., 1999 J Biol Chem 274(44):31305-31311		
	CY	Nielsen et al., 1988 J. Biol Chem 263(5):2358-2363		
	CZ	Nykjaer et al., 1997 EMBO J 16(10):2610-2620		
	CA1	Olson et al., 1992 J Biol Chem 267(13):9129-9133		
	CB1	Ploug et al., 1991 J Biol Chem 266(3):1926-1933		
	CC1	Reijerkerk et al., 2000 Eur J Cancer, 36:1695-1705		
	CD1	Richardson, 2000 Eur J. Biochem 267:1290-1298		
	CE1	Sekyere et al., 2000 FEBS Letters 483:11-16		
	CF1	Stahl et al., 1997 Int J Cancer 71:116-122		
	CG1	Tarui et al., 2002 J Biol Chem 277(37):33564-33570		
	CH1	Weaver et al., 1997 J Biol Chem 272(22):14372-14379		
	CI1	Woodbury et al., 1980 Proc Natl Acad Sci USA 77(4):2183-2187		
/AMG/	CJ1	Woodbury et al., 1981, Int J Cancer, 27:145-149		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Anne Gussow/	Date Considered	10/05/2007
--------------------	---------------	-----------------	------------